Enzyme, AEB3103, Kills Prostate Cancer Cells by Unleashing Oxidative Stress in Mice Study November 23, 2016 Aeglea BioTherapeutics’ investigational enzyme, AEB3103, seems a promising treatment approach for a number of tumors, according to preclinical study results. The therapy suppressed tumor growth in prostate and breast cancer mouse models, and improved survival in a model of chronic lymphocytic leukemia (CLL). Read more here.Source: Prostate Cancer News Today Prostate Cancer News
Aeglea BioTherapeutics’ investigational enzyme, AEB3103, seems a promising treatment approach for a number of tumors, according to preclinical study results. The therapy suppressed tumor growth in prostate and breast cancer mouse models, and improved survival in a model of chronic lymphocytic leukemia (CLL). Read more here.Source: Prostate Cancer News Today
Complete the Survey
